First-pass extracted concept

CAR-based cell therapy

Candidate: concept label1 source documents5 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

CAR-based therapies, chimeric antigen receptor (CAR)-based cell therapies

Evidence Snippets

Chimeric antigen receptor (CAR)-based cell therapies, initially designed for oncology, are rapidly advancing as a novel and highly targeted approach for the treatment of autoimmune diseases (AIDs).

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1design principlesupports2025Source 1DOI PubMed

Antigen selection, co-stimulatory domains, and safety control mechanisms are critical CAR design features for improving therapeutic precision and reducing side effects.

Claim 2future outlooksupports2025Source 1DOI PubMed

Current developments support the potential of CAR-based therapies as a next-generation option for autoimmune disease treatment.

Claim 3mechanism of actionsupports2025Source 1DOI PubMed

CAR-based strategies for autoimmune disease aim to eliminate autoreactive immune components or restore immune homeostasis.

Claim 4therapeutic potentialsupports2025Source 1DOI PubMed

CAR-based cell therapies are advancing as a highly targeted approach for treatment of autoimmune diseases.

Claim 5translation challengesupports2025Source 1DOI PubMed

Major challenges for clinical translation of CAR-based therapies in autoimmune disease include antigen specificity, long-term persistence, and manufacturing feasibility.